Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Sana Biotechnology Inc — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.25, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | SANA | |
|---|---|---|
52-Week High | $75.17 | $5.92 |
52-Week Low | $72.15 | $2.68 |
Market Cap | — | $1.13B |
Sector | — | Health |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.28, up 0.18% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include dividend payments of $0.25-$0.24, with the next scheduled for August 5, 2026. The ETF's neutral oscillators and flat support/resistance at $72 suggest consolidation. News highlights focus on bond ETF inflows and institutional positioning shifts.
The outlook remains cautious amid rising Treasury yields and inflation concerns. Opportunities lie in BND's role as a core fixed-income holding for diversification, but risks include interest rate sensitivity and macroeconomic volatility. Investor sentiment is mixed, balancing yield appeal against bond market headwinds.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
